

Jacques A. Machol IV, MD; William W. Dzwierzynski, MD


Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA J.A.M. has nothing to disclose W.W.D. is a consultant and speaker for Auxilium, Xiaflex®



Introduction

- Subungual melanoma is a relatively rare disease that carries a poor prognosis¹⁻³
- Several retrospective studies have been conducted, but incidence, recurrence, and survival rates vary greatly depending on the investigation¹⁻²⁰
- Current NCCN guidelines also offer little insight as to the specific surgical management of subungual melanoma²¹
- We aim to utilize a systematic review to better appraise this pathology and to examine applicable surgical interventions

Introduction







Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Methods

- A Meta-Analysis provides comparison of similar, randomized controlled studies to increase sample size
- Unfortunately, no such prospective trials exist specifically for treatment of subungual melanoma
- A **Systematic Review** is elected as this allows the compilation of study data from case series that are nonrandomized or controlled

Methods

- A systematic lit. review using MEDLINE was performed
- "Subungual Melanoma" or "Subungual Melanosis"
- 1965 to 2012
- English language, Human citations



Fig. 2. Clinical presentation of subungual melanoma as a nail streak





Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery

Medical College of Wisconsin, Milwaukee, WI, USA



Methods


Inclusion:

- F/u adequate to determine 5 year survival
- >5 cases (to exclude case reports)
- Surgical treatment data
- Hand +/- foot
- Pathology data or clinical presentation or trauma data

Exclusion:

- <5 cases
- Lower extremity only
- Treatment specific (ex. specific surgical technique, ILP only)
- Histologic, pathologic, or basic science studies with no treatment (i.e. Acral or in-situ only)
- No surgical data





Methods

Fig. 3. Attrition Search



Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



- 117 sources were reviewed
- **16** met the established review criteria^{1,2,4,5,7-18}

Author	Year	PMID#	Study Dates	# of Patients	Study Design	Sex Male	Sex Female	Caucasian	Black	Other or Unknown	Population	Age Mean (Years)	Age Range	Follow Up
Cohen et al ⁹	2008	18086464	1992-2004	49	RR	18	31	39	4	6	NYC, NY	66	24-83	38 months
O'Leary et al ¹⁴	2000	10986996	1970-1996	93	RR	53	40	82	11	0	Duke, NC	55.4	10-84	5.2 years
Quinn et al ⁴	1996	8724488	1950-1994	38	RR	24	14	38	0	0	Sydney, Australia	59	33-82	53 months
Kridge et al ¹³	1995	7631249	1970-1986	20	RR	8	12	7	13	0	Cape Town, South Africa	51.3	22-79	Not mentioned
Finely et al ³	1994	8023276	1971-1989	22	RR	12	10	o	0	o	Buffalo, NY	59	×	33 months (median)
Heaton et al ¹¹	1994	8129491	1956-1988	46	RR	46	18	0	0	0	Houston, TX	59.5	22-83	9.5 years (median)
Parket al ¹⁶	1992	1466623	1979-1989	100	RR	o	0	0	0	0	Aberdeen, Scotland	67	33-93	Not mentioned
Rigby and Briggs ¹⁷	1992	1623342	1967-1991	24	RR	11	13	0	0	o	Bristol, UK	61.6	16-96	3 months - 18 years
Hudson et al ¹²	1990	2230492	1970-1987	13	RR	7	6	5	3	3	Cape Town, South Africa	47.5	22-79	Up to 36 months
Daly et al ¹⁰	1987	3586679	1950-1975	33	RR	11	22	28	3	2	NYC, NY	56	28-89	8 year min
Takematsu et al ¹⁸	1985	3995482	1969-1982	16	RR	12	14	0	0	0	Sendai, Japan	56	30-84	Up to 110 months
Papachristou and Fortner ¹⁵	1982	7144198	1956-1976	52	RR	25	27	0	o	0	NYC, NY	65	28-88	Not mentioned
Patterson and Helwig ⁷	1980	7427913	Not Mentioned	66	RR	44	22	56	3	7	Washington D.C.	61	23-95	Not mentioned
Welvaart and Schraffordt Koops ²⁰	1978	365409	1966-1976	25	RR	12.50	12.5	0	0	0	The Netherlands	64	×	9 mo - 10 years
Pack and Opreza ¹⁹	1967	6018519	1932-1967	72	RR	32	40	o	0	o	NYC, NY	57	27-79	Not mentioned
Das Gupta and Brasfield ⁶	1965	PMC14089 99	1929-1964	34	RR	14	20	0	0	o	NYC, NY	26/34 over 50 (2 below 29)	×	Not mentioned





Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Results

- Mean age of **47.2 years** (range 10 to 96)
- M to F ratio 1.09 to 1.00
- Caucasians were affected more than the other races (82%)
- Incidence: 3.03% of cutaneous melanomas (range 0.31-16%)




Fig. 4. Incidence of subungual melanoma presenting for treatment






Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Results

- Thumb 60% of hand cases
- Hallux 78% of lower extremity cases
- 55% presented with discoloration or nail bed lesion as their primary symptom
- 34% reported a history of digit trauma
- Average delay to diagnosis was a staggering 18.7 months (range 12-30 months)







Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



- 4.22 mm mean Breslow depth (range 2.1-6.1 mm)
- Clark's level IV or V was by in far the most common
- 100 of the 213 reported patients were Stage I
- 72, 33 and 8, were Stages II, III, and IV respectively
- Mitotic figures were reported in only one study
- 59% of lesions were with ulceration
- Acral lentiginous most common clinicopathologic variant (57%)






Fig. 5. Stages of Subungual Melanoma




Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Results

- Surgical details for 645/669 total cases found
- Amputation was the most common treatment occurring 95% of the time
- The proper level of amputation was a controversial topic among the reviewed manuscripts
- Newer studies recommended more distal amputation - IP or PIP level of amputation were most common
- Utilized 63% of the time in the hand
- MTP joint or more proximal amputation was performed most often in lower extremities (99%)







Froedtert &

Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Results

- The majority of studies did not specify if an <u>upper</u> or <u>lower</u> extremity was treated with a specific procedure
- These were categorized into:
 - Amputation at or distal to the DIP/IP or
 - Amputation **proximal** to the DIP/IP
- After data merger, proximal amputation predominated 67% of the time

- 30 sentinel lymph node biopsies (SLNB) were recorded
- 5/30 were positive
- All five positive biopsies underwent lymph node dissection and one was positive
- 241 patients had therapeutic or elective node dissections
- Of these, 45% had positive nodes






Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Results

- No study reported surgical complications
- Local or distant recurrence was noted in 27% of cases
- Unable to elucidate the exact number of overall local versus distant recurrences from the data available
- Overall mean 5-year survival was 46% across the studies
- 5-year survival for stage I disease was **55%**
- 5-year survival for stage II or greater disease was a dismal **35%**

Results Five Year Survival







Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Conclusions

- Mean age across the studies 47.2 years
- Younger versus mean age of cutaneous melanoma diagnosis (61 years)²²
- Marked delay in diagnosis (18.7 months)
- Earlier recognition of this disease may improve survival
- Suspicious subungual lesions should be biopsied to rule out neoplastic disease (<4wks)²³

Conclusions

- Trauma was noted in only 1/3 of the cases
- Likely not causative of malignant changes. May increase attention to changes in the nail bed
- Exceedingly invasive disease (4.2mm), yet does not correlate with low mean stage (I or II)
- Demonstrates how obtaining a true depth
 is difficult
- Overall, majority of studies conclude stage as the most indicative factor of patient prognosis





Jacques A. Machol IV, MD, William W. Dzwierzynski, MD Department of Plastic Surgery Medical College of Wisconsin, Milwaukee, WI, USA



Conclusions

- Continue to stage per guidelines until further studies available²¹
- The current evidence <u>does not</u> demonstrate improved survival with a more proximal amputation^{9,13}
- Recommend DIP or IP amputation for primary lesions

Conclusions

- Node dissection should be reserved for clinically positive nodes and for positive lymph node biopsy until additional data is available²¹
- Future studies are required to modify the staging system for this insidious pathology



References

- 1. Finley RK,3rd, Driscoll DL, Blumenson LE, Karakousis CP. Subungual melanoma: An eighteen-year review. Surgery. 1994 Jul;116(1):96-100.
- 2. Quinn MJ, Thompson JE, Crotty K, McCarthy WH, Coates AS. Subungual melanoma of the hand. J Hand Surg Am. 1996 May;21(3):506-11.
- 3. Glat PM, Spector JA, Roses DF, Shapiro RA, Harris MN, Beasley RW, et al. The management of pigmented lesions of the nail bed. Ann Plast Surg. 1996 Aug;37(2):125-34.
- 4. Das Gupata T, Brasfield R. Subungual melanoma: 25-year review of cases. Ann Surg. 1965 Apr;161:545-52.
- 5. Patterson RH, Helwig EB. Subungual malignant melanoma: A clinical-pathologic study. Cancer. 1980 Nov 1;46(9):2074-87.
- 6. Martin DE, English JC, Goitz RJ. Subungual malignant melanoma. J Hand Surg Am. 2011 Apr;36(4):704-7.
- 7. Cohen T, Busam KJ, Patel A, Brady MS. Subungual melanoma: Management considerations. Am J Surg. 2008 Feb;195(2):244-8.
- 8. Daly JM, Berlin R, Urmacher C. Subungual melanoma: A 25-year review of cases. J Surg Oncol. 1987 Jun;35(2):107-12.
- 9. Heaton KM, el-Naggar A, Ensign LG, Ross MI, Balch CM. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg. 1994 Feb;219(2):197-204.
- 10. Hudson DA, Krige JE, Strover RM, King HS. Subungual melanoma of the hand. J Hand Surg Br. 1990 Aug;15(3):288-90.
- 11. Krige JE, Hudson DA, Johnson CA, King HS, Chetty R. Subungual melanoma. S Afr J Surg. 1995 Mar;33(1):10-4.
- 12. O'Leary JA, Berend KR, Johnson JL, Levin LS, Seigler HF. Subungual melanoma. A review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res. 2000 Sep;(378)(378):206-12.
- 13. Papachristou DN, Fortner JG. Melanoma arising under the nail. J Surg Oncol. 1982 Dec;21(4):219-22.
- 14. Park KG, Blessing K, Kernohan NM. Surgical aspects of subungual malignant melanomas. the scottish melanoma group. Ann Surg. 1992 Dec;216(6):692-5.
- 15. Rigby HS, Briggs JC. Subungual melanoma: A clinico-pathological study of 24 cases. Br J Plast Surg. 1992 May-Jun;45(4):275-8.
- 16. Takematsu H, Obata M, Tomita Y, Kato T, Takahashi M, Abe R. Subungual melanoma. A clinicopathologic study of 16 japanese cases. Cancer. 1985 Jun 1;55(11):2725-31.
- 17. Pack GT, Oropeza R. Subungual melanoma. Surg Gynecol Obstet. 1967 Mar;124(3):571-82.
- 18. Welvaart K, Schraffordt Koops H. Subungual malignant melanoma: A nail in the coffin. Clin Oncol. 1978 Dec;4(4):309-15.
- 19. Feibleman CE, Stoll H, Maize JC. Melanomas of the palm, sole, and nailbed: A clinicopathologic study. Cancer. 1980 Dec 1;46(11):2492-504.
- 20. Briggs JC. Subungual malignant melanoma: A review article. Br J Plast Surg. 1985 Apr;38(2):174-6.
- 21. American Joint Committee on Cancer (AJCC) Classification. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 1.2013. [Internet].; 2012. Available from: <u>http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf</u>.
- 22. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
- 23. O'Connor EA, Dzwierzynski W. Longitudinal melonychia: Clinical evaluation and biopsy technique. J Hand Surg Am. 2011 Nov;36(11):1852-4.



